DiaMedica Therapeutics (DMAC) FDA Approvals $5.77 +0.05 (+0.87%) Closing price 04:00 PM EasternExtended Trading$5.78 +0.01 (+0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DiaMedica Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by DiaMedica Therapeutics (DMAC). Over the past two years, DiaMedica Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as DM199. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. DM199 FDA Regulatory Timeline and Events DM199 is a drug developed by DiaMedica Therapeutics for the following indication: Chronic Kidney Disease Stage II or III. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Enrollment Update - May 20,2026Enrollment Update Phase 2/3Drug: DM199Announced Date: May 20, 2026Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the 200-patient threshold required to trigger the planned interim analysis.AI SummaryDiaMedica Therapeutics said enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199, also called rinvecalinase alfa, has reached 75% of the 200-patient level needed to start a planned interim analysis. The study is testing DM199 in people with acute ischemic stroke, a serious type of stroke caused by blocked blood flow to the brain. The interim review will be done by an independent Data Safety Monitoring Board. Its job is to decide whether the trial should be adjusted, including whether the sample size should be re-estimated. DiaMedica said this step is meant to help make sure the study has enough power to show success while protecting the trial’s integrity. The company will not see the detailed interim results. DM199 is designed to improve blood flow and help protect brain tissue by acting on a natural human enzyme involved in circulation and inflammation.Read AnnouncementNo Objection Letter - March 5,2026No Objection Letter Health CanadaDrug: DM199Announced Date: March 5, 2026Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics In c nnounced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase 2 trial in patients with early-onset preeclampsia (PE).AI SummaryDiaMedica Therapeutics Inc. announced it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to study DM199 in a Phase 2 trial for patients with early-onset preeclampsia. The NOL clears the way for DiaMedica to initiate the Phase 2 study in Canada, advancing clinical evaluation of DM199—also known as rinvecalinase alfa—as a potential treatment for this serious pregnancy complication. The company noted that its DM199 preeclampsia program recently received coverage on National Public Radio, raising public awareness. DiaMedica also included the usual cautionary language about forward-looking statements, reminding readers that trial timing and outcomes are subject to risks and uncertainties. The NOL represents a key regulatory step toward testing DM199’s safety and effectiveness in the targeted patient population. Read AnnouncementProvided Update - December 18,2025Provided Update Pre-IND MeetingDrug: DM199Announced Date: December 18, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia.AI SummaryDiaMedica announced it completed a productive in-person pre-IND meeting with the U.S. Food and Drug Administration about a planned study of DM199 for preeclampsia. Meeting minutes show the FDA requested one additional non-clinical study: a 10-day modified embryo-fetal development (EFD) and pre- and postnatal development (PPND) study in rabbits. DiaMedica has started preparations for that study and expects results by the second quarter of 2026. Company leadership said the meeting minutes give important regulatory clarity as they prepare an IND for a study in early-onset preeclampsia. DiaMedica also said it will continue to engage with the FDA as it advances development of DM199. The company noted ongoing clinical work, including an investigator-sponsored Phase 2 trial that has dosed over 30 women with late-stage preeclampsia and shown encouraging safety and efficacy signals to date.Read AnnouncementPositive Results - July 17,2025Positive Results Phase 2Drug: DM199Announced Date: July 17, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia.AI SummaryDiaMedica Therapeutics Inc. announced positive interim results from Part 1a of its Phase 2 study evaluating DM199 for the treatment of preeclampsia. In the dose-escalation phase, DM199 showed highly statistically significant and clinically meaningful reductions in both systolic and diastolic blood pressure. In addition, the treatment significantly reduced the uterine artery pulsatility index, indicating improved placental perfusion. Most importantly, DM199 did not cross the placental barrier and was well tolerated, addressing a major safety concern in preeclampsia treatment. These encouraging outcomes support DM199’s potential as a first-in-class, disease-modifying therapy for a condition with no approved pharmacological treatments in the United States and Europe. The positive safety and efficacy benchmarks meet key study endpoints and bolster further investigation into the drug's role in improving maternal and fetal health in this underserved patient population.Read AnnouncementPublication - February 20,2025Publication Drug: DM199Announced Date: February 20, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced the peer-reviewed publication entitled:Recombinant human tissue kallikrein-1 for treating acute ischemic stroke and preventing recurrence (Kasner, et al.) which is now available online and is scheduled for print publication in the February 2025 issue of Stroke.AI SummaryDiaMedica Therapeutics Inc. announced that a new peer-reviewed article, "Recombinant human tissue kallikrein-1 for treating acute ischemic stroke and preventing recurrence" (Kasner et al.), is now available online and will appear in the February 2025 issue of Stroke. This publication explains how DM199, a recombinant form of human tissue kallikrein-1, works to treat acute ischemic stroke by increasing collateral circulation and protecting brain tissue. The study shows that DM199 boosts the production of bradykinin, a substance that dilates blood vessels in the brain, enhancing blood flow and promoting the formation of new blood vessels, which may help repair injured tissue. These findings provide important scientific insight into DM199’s potential to improve outcomes in stroke patients by enhancing blood circulation in the affected brain regions, offering a novel approach to stroke treatment.Read AnnouncementProvided Update - December 3,2024Provided Update Drug: DM199Announced Date: December 3, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announce the formation of its Scientific Advisory Board (SAB) to support the development of DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia (PE).AI SummaryDiaMedica Therapeutics Inc. announced the formation of its new Scientific Advisory Board (SAB) to help guide the development of DM199, a proprietary recombinant serine protease aimed at treating preeclampsia (PE). The SAB is made up of renowned experts in PE and maternal-fetal health who will work closely with DiaMedica’s leadership. Their expert guidance is expected to accelerate the research and clinical strategies needed to bring DM199 closer to providing a safe and effective treatment for this life-threatening condition. Rick Pauls, President and CEO, highlighted his excitement for the collaboration, emphasizing that the insights from these distinguished doctors will play a key role in advancing care for women and their babies facing preeclampsia. This strategic move marks an important step forward in DiaMedica’s efforts to develop innovative treatments for serious pregnancy-related disorders.Read AnnouncementDose Update - October 9,2024Dose Update Drug: DM199Announced Date: October 9, 2024Target Action Date: Q4 2024Estimated Target Date Range: October 1, 2024 - December 31, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics announced that Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025AI SummaryDiaMedica Therapeutics announced that it is set to begin dosing the first participant in its Phase 2 clinical trial in the fourth quarter of 2024. This trial will focus on testing DM199, the company’s proprietary recombinant serine protease, to treat preeclampsia. The study aims to assess whether DM199 is safe and if it can effectively improve maternal blood pressure and placental blood flow. Preliminary proof-of-concept results are expected to be available in the first half of 2025. These early findings will be crucial in determining the drug’s potential to offer a new treatment option for preeclampsia, a condition that poses significant risks to both mothers and their babies. The upcoming milestones mark important steps toward understanding and addressing this serious pregnancy disorder.Read AnnouncementReceived Approval - October 9,2024Received Approval Phase 2Drug: DM199Announced Date: October 9, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia.AI SummaryDiaMedica Therapeutics Inc. announced that it has received regulatory approval from the South African Health Products Regulatory Authority to start a Phase 2 clinical trial using its proprietary recombinant serine protease, DM199, to treat preeclampsia. The trial will be conducted at Tygerberg Hospital in Cape Town under the direction of Professor Catherine Cluver, MD, PhD. Researchers will assess whether DM199 can safely lower maternal blood pressure, improve endothelial health, and increase placental blood flow, potentially leading to longer gestational periods and healthier outcomes for both mothers and babies. Dosing of the first participant is scheduled to begin in the fourth quarter of 2024, with preliminary proof-of-concept results expected in the first half of 2025. This trial represents an important step toward developing the first targeted therapeutic option for preeclampsia.Read AnnouncementProvided Update - July 11,2024Provided Update Drug: DM199Announced Date: July 11, 2024Target Action Date: July 19, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.AI SummaryDiaMedica Therapeutics Inc. has announced a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET. The event will highlight the company’s plans to expand its clinical development program for DM199 (rinvecalinase alfa) into treating preeclampsia—a serious pregnancy disorder with no FDA-approved treatments. The session will feature expert speakers who will discuss the urgent need for new therapies and explore how DM199 works. DM199 aims to improve blood flow and lower blood pressure by boosting the production of nitric oxide, prostacyclin, and other factors that support vascular health in both the mother and placenta. A live question and answer session will follow, offering attendees an opportunity to engage directly with the experts during the event.Read AnnouncementProvided Update - June 26,2024Provided Update Phase 2Drug: DM199Announced Date: June 26, 2024Target Action Date: Q4 2024Estimated Target Date Range: October 1, 2024 - December 31, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced that Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024AI SummaryDiaMedica Therapeutics Inc. announced it will initiate its Phase 2 investigator-sponsored trial for preeclampsia in the fourth quarter of 2024. The trial will study DM199, a recombinant human tissue kallikrein-1 protein, as a potential treatment to lower blood pressure and improve maternal blood flow through the placenta. This approach could address a life-threatening vascular disorder during pregnancy that currently has no approved therapeutics in the U.S. or Europe. The study plans to enroll up to 120 participants, with preliminary proof-of-concept results expected by the first half of 2025. The trial is designed to assess safety, blood pressure reduction, and the drug’s ability to dilate intrauterine arteries without crossing the placental barrier, which could offer a significant safety advantage. The Phase 2 trial represents a key expansion of DiaMedica’s clinical development program in addressing a critical unmet medical need in pregnancy disorders.Read AnnouncementResults - June 26,2024Results Drug: DM199Announced Date: June 26, 2024Target Action Date: H1 2025Estimated Target Date Range: January 1, 2025 - June 30, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced that Key Proof-of-Concept Results Expected in the First Half of 2025AI SummaryDiaMedica Therapeutics Inc. announced plans for a Phase 2 investigator-sponsored trial to explore its novel treatment DM199 for preeclampsia. The study, which is set to begin enrolling participants in the fourth quarter of 2024, will evaluate DM199’s ability to safely lower blood pressure and improve blood flow to the placenta without crossing the placental barrier. The trial, conducted in South Africa at Tygerberg Hospital, is designed to be capital efficient by enrolling up to 120 participants. DiaMedica expects to generate key proof-of-concept results in the first half of 2025. These results will be critical in determining whether DM199 can provide a safe and effective treatment option for preeclampsia, a serious condition with significant risks to both mother and baby. This potential breakthrough could offer hope in an area where no FDA-approved therapies currently exist.Read AnnouncementProvided Update - June 26,2024Provided Update Drug: DM199Announced Date: June 26, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia.AI SummaryDiaMedica Therapeutics Inc. announced plans to expand its DM199 clinical development program into preeclampsia, a serious pregnancy-related condition marked by high blood pressure and potential organ damage. DM199, a recombinant human tissue kallikrein-1 protein, has shown promise in lowering blood pressure and improving blood flow. Unlike small molecule anti-hypertensive drugs, DM199 is a large molecule that does not cross the placental barrier in animal studies, suggesting a safety advantage for pregnant women. The company will launch a Phase 2 investigator-sponsored trial in the fourth quarter of 2024 to assess DM199’s safety and effectiveness in treating preeclampsia. The trial aims to enroll up to 120 participants at a cost-efficient price, with initial proof-of-concept results expected in the first half of 2025. This development could offer new hope for managing a condition that currently has no approved treatments in the U.S. or Europe.Read Announcement DiaMedica Therapeutics FDA Events - Frequently Asked Questions Has DiaMedica Therapeutics received FDA approval? As of now, DiaMedica Therapeutics (DMAC) has not received any FDA approvals for its therapy in the last two years. What drugs has DiaMedica Therapeutics submitted to the FDA? In the past two years, DiaMedica Therapeutics (DMAC) has reported FDA regulatory activity for DM199. What is the most recent FDA event for DiaMedica Therapeutics? The most recent FDA-related event for DiaMedica Therapeutics occurred on May 20, 2026, involving DM199. The update was categorized as "Enrollment Update," with the company reporting: "DiaMedica Therapeutics Inc announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the 200-patient threshold required to trigger the planned interim analysis." What conditions do DiaMedica Therapeutics' current drugs treat? Currently, DiaMedica Therapeutics has one therapy (DM199) targeting the following condition: Chronic Kidney Disease Stage II or III. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagio Medical FDA EventsBioCardia FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsPrecision BioSciences FDA EventsHUTCHMED FDA EventsEli Lilly and Company FDA EventsTeleflex FDA EventsBioMarin Pharmaceutical FDA EventsDiaMedica Therapeutics FDA EventsDyne Therapeutics FDA EventsGuardant Health FDA EventsLigand Pharmaceuticals FDA EventsMadrigal Pharmaceuticals FDA EventsMetaVia FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies WAVE Life Sciences FDA Events MoonLake Immunotherapeutics FDA Events AbCellera Biologics FDA Events Maplight Therapeutics FDA Events Septerna FDA Events Olema Pharmaceuticals FDA Events Harrow FDA Events Jade Biosciences FDA Events Collegium Pharmaceutical FDA Events DBV Technologies FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:DMAC last updated on 5/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Enrollment Update - May 20,2026Enrollment Update Phase 2/3Drug: DM199Announced Date: May 20, 2026Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the 200-patient threshold required to trigger the planned interim analysis.AI SummaryDiaMedica Therapeutics said enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199, also called rinvecalinase alfa, has reached 75% of the 200-patient level needed to start a planned interim analysis. The study is testing DM199 in people with acute ischemic stroke, a serious type of stroke caused by blocked blood flow to the brain. The interim review will be done by an independent Data Safety Monitoring Board. Its job is to decide whether the trial should be adjusted, including whether the sample size should be re-estimated. DiaMedica said this step is meant to help make sure the study has enough power to show success while protecting the trial’s integrity. The company will not see the detailed interim results. DM199 is designed to improve blood flow and help protect brain tissue by acting on a natural human enzyme involved in circulation and inflammation.Read Announcement
No Objection Letter - March 5,2026No Objection Letter Health CanadaDrug: DM199Announced Date: March 5, 2026Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics In c nnounced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase 2 trial in patients with early-onset preeclampsia (PE).AI SummaryDiaMedica Therapeutics Inc. announced it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to study DM199 in a Phase 2 trial for patients with early-onset preeclampsia. The NOL clears the way for DiaMedica to initiate the Phase 2 study in Canada, advancing clinical evaluation of DM199—also known as rinvecalinase alfa—as a potential treatment for this serious pregnancy complication. The company noted that its DM199 preeclampsia program recently received coverage on National Public Radio, raising public awareness. DiaMedica also included the usual cautionary language about forward-looking statements, reminding readers that trial timing and outcomes are subject to risks and uncertainties. The NOL represents a key regulatory step toward testing DM199’s safety and effectiveness in the targeted patient population. Read Announcement
Provided Update - December 18,2025Provided Update Pre-IND MeetingDrug: DM199Announced Date: December 18, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia.AI SummaryDiaMedica announced it completed a productive in-person pre-IND meeting with the U.S. Food and Drug Administration about a planned study of DM199 for preeclampsia. Meeting minutes show the FDA requested one additional non-clinical study: a 10-day modified embryo-fetal development (EFD) and pre- and postnatal development (PPND) study in rabbits. DiaMedica has started preparations for that study and expects results by the second quarter of 2026. Company leadership said the meeting minutes give important regulatory clarity as they prepare an IND for a study in early-onset preeclampsia. DiaMedica also said it will continue to engage with the FDA as it advances development of DM199. The company noted ongoing clinical work, including an investigator-sponsored Phase 2 trial that has dosed over 30 women with late-stage preeclampsia and shown encouraging safety and efficacy signals to date.Read Announcement
Positive Results - July 17,2025Positive Results Phase 2Drug: DM199Announced Date: July 17, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia.AI SummaryDiaMedica Therapeutics Inc. announced positive interim results from Part 1a of its Phase 2 study evaluating DM199 for the treatment of preeclampsia. In the dose-escalation phase, DM199 showed highly statistically significant and clinically meaningful reductions in both systolic and diastolic blood pressure. In addition, the treatment significantly reduced the uterine artery pulsatility index, indicating improved placental perfusion. Most importantly, DM199 did not cross the placental barrier and was well tolerated, addressing a major safety concern in preeclampsia treatment. These encouraging outcomes support DM199’s potential as a first-in-class, disease-modifying therapy for a condition with no approved pharmacological treatments in the United States and Europe. The positive safety and efficacy benchmarks meet key study endpoints and bolster further investigation into the drug's role in improving maternal and fetal health in this underserved patient population.Read Announcement
Publication - February 20,2025Publication Drug: DM199Announced Date: February 20, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced the peer-reviewed publication entitled:Recombinant human tissue kallikrein-1 for treating acute ischemic stroke and preventing recurrence (Kasner, et al.) which is now available online and is scheduled for print publication in the February 2025 issue of Stroke.AI SummaryDiaMedica Therapeutics Inc. announced that a new peer-reviewed article, "Recombinant human tissue kallikrein-1 for treating acute ischemic stroke and preventing recurrence" (Kasner et al.), is now available online and will appear in the February 2025 issue of Stroke. This publication explains how DM199, a recombinant form of human tissue kallikrein-1, works to treat acute ischemic stroke by increasing collateral circulation and protecting brain tissue. The study shows that DM199 boosts the production of bradykinin, a substance that dilates blood vessels in the brain, enhancing blood flow and promoting the formation of new blood vessels, which may help repair injured tissue. These findings provide important scientific insight into DM199’s potential to improve outcomes in stroke patients by enhancing blood circulation in the affected brain regions, offering a novel approach to stroke treatment.Read Announcement
Provided Update - December 3,2024Provided Update Drug: DM199Announced Date: December 3, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announce the formation of its Scientific Advisory Board (SAB) to support the development of DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia (PE).AI SummaryDiaMedica Therapeutics Inc. announced the formation of its new Scientific Advisory Board (SAB) to help guide the development of DM199, a proprietary recombinant serine protease aimed at treating preeclampsia (PE). The SAB is made up of renowned experts in PE and maternal-fetal health who will work closely with DiaMedica’s leadership. Their expert guidance is expected to accelerate the research and clinical strategies needed to bring DM199 closer to providing a safe and effective treatment for this life-threatening condition. Rick Pauls, President and CEO, highlighted his excitement for the collaboration, emphasizing that the insights from these distinguished doctors will play a key role in advancing care for women and their babies facing preeclampsia. This strategic move marks an important step forward in DiaMedica’s efforts to develop innovative treatments for serious pregnancy-related disorders.Read Announcement
Dose Update - October 9,2024Dose Update Drug: DM199Announced Date: October 9, 2024Target Action Date: Q4 2024Estimated Target Date Range: October 1, 2024 - December 31, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics announced that Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025AI SummaryDiaMedica Therapeutics announced that it is set to begin dosing the first participant in its Phase 2 clinical trial in the fourth quarter of 2024. This trial will focus on testing DM199, the company’s proprietary recombinant serine protease, to treat preeclampsia. The study aims to assess whether DM199 is safe and if it can effectively improve maternal blood pressure and placental blood flow. Preliminary proof-of-concept results are expected to be available in the first half of 2025. These early findings will be crucial in determining the drug’s potential to offer a new treatment option for preeclampsia, a condition that poses significant risks to both mothers and their babies. The upcoming milestones mark important steps toward understanding and addressing this serious pregnancy disorder.Read Announcement
Received Approval - October 9,2024Received Approval Phase 2Drug: DM199Announced Date: October 9, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia.AI SummaryDiaMedica Therapeutics Inc. announced that it has received regulatory approval from the South African Health Products Regulatory Authority to start a Phase 2 clinical trial using its proprietary recombinant serine protease, DM199, to treat preeclampsia. The trial will be conducted at Tygerberg Hospital in Cape Town under the direction of Professor Catherine Cluver, MD, PhD. Researchers will assess whether DM199 can safely lower maternal blood pressure, improve endothelial health, and increase placental blood flow, potentially leading to longer gestational periods and healthier outcomes for both mothers and babies. Dosing of the first participant is scheduled to begin in the fourth quarter of 2024, with preliminary proof-of-concept results expected in the first half of 2025. This trial represents an important step toward developing the first targeted therapeutic option for preeclampsia.Read Announcement
Provided Update - July 11,2024Provided Update Drug: DM199Announced Date: July 11, 2024Target Action Date: July 19, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.AI SummaryDiaMedica Therapeutics Inc. has announced a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET. The event will highlight the company’s plans to expand its clinical development program for DM199 (rinvecalinase alfa) into treating preeclampsia—a serious pregnancy disorder with no FDA-approved treatments. The session will feature expert speakers who will discuss the urgent need for new therapies and explore how DM199 works. DM199 aims to improve blood flow and lower blood pressure by boosting the production of nitric oxide, prostacyclin, and other factors that support vascular health in both the mother and placenta. A live question and answer session will follow, offering attendees an opportunity to engage directly with the experts during the event.Read Announcement
Provided Update - June 26,2024Provided Update Phase 2Drug: DM199Announced Date: June 26, 2024Target Action Date: Q4 2024Estimated Target Date Range: October 1, 2024 - December 31, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc announced that Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024AI SummaryDiaMedica Therapeutics Inc. announced it will initiate its Phase 2 investigator-sponsored trial for preeclampsia in the fourth quarter of 2024. The trial will study DM199, a recombinant human tissue kallikrein-1 protein, as a potential treatment to lower blood pressure and improve maternal blood flow through the placenta. This approach could address a life-threatening vascular disorder during pregnancy that currently has no approved therapeutics in the U.S. or Europe. The study plans to enroll up to 120 participants, with preliminary proof-of-concept results expected by the first half of 2025. The trial is designed to assess safety, blood pressure reduction, and the drug’s ability to dilate intrauterine arteries without crossing the placental barrier, which could offer a significant safety advantage. The Phase 2 trial represents a key expansion of DiaMedica’s clinical development program in addressing a critical unmet medical need in pregnancy disorders.Read Announcement
Results - June 26,2024Results Drug: DM199Announced Date: June 26, 2024Target Action Date: H1 2025Estimated Target Date Range: January 1, 2025 - June 30, 2025Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced that Key Proof-of-Concept Results Expected in the First Half of 2025AI SummaryDiaMedica Therapeutics Inc. announced plans for a Phase 2 investigator-sponsored trial to explore its novel treatment DM199 for preeclampsia. The study, which is set to begin enrolling participants in the fourth quarter of 2024, will evaluate DM199’s ability to safely lower blood pressure and improve blood flow to the placenta without crossing the placental barrier. The trial, conducted in South Africa at Tygerberg Hospital, is designed to be capital efficient by enrolling up to 120 participants. DiaMedica expects to generate key proof-of-concept results in the first half of 2025. These results will be critical in determining whether DM199 can provide a safe and effective treatment option for preeclampsia, a serious condition with significant risks to both mother and baby. This potential breakthrough could offer hope in an area where no FDA-approved therapies currently exist.Read Announcement
Provided Update - June 26,2024Provided Update Drug: DM199Announced Date: June 26, 2024Indication: Chronic Kidney Disease Stage II or IIIAnnouncementDiaMedica Therapeutics Inc. announced that it plans to expand its DM199 (rinvecalinase alfa; recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program into preeclampsia.AI SummaryDiaMedica Therapeutics Inc. announced plans to expand its DM199 clinical development program into preeclampsia, a serious pregnancy-related condition marked by high blood pressure and potential organ damage. DM199, a recombinant human tissue kallikrein-1 protein, has shown promise in lowering blood pressure and improving blood flow. Unlike small molecule anti-hypertensive drugs, DM199 is a large molecule that does not cross the placental barrier in animal studies, suggesting a safety advantage for pregnant women. The company will launch a Phase 2 investigator-sponsored trial in the fourth quarter of 2024 to assess DM199’s safety and effectiveness in treating preeclampsia. The trial aims to enroll up to 120 participants at a cost-efficient price, with initial proof-of-concept results expected in the first half of 2025. This development could offer new hope for managing a condition that currently has no approved treatments in the U.S. or Europe.Read Announcement
